ArticleBMC public health2025
PrEP public policies for HIV prevention in South America: an intersectional analysis.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundHIV pre-exposure prophylaxis (PrEP) is a highly effective biomedical prevention strategy, recommended by the World Health Organization since 2015. However, in South America, its adoption has been uneven, reflecting structural, political, and socio-cultural inequalities. This study maps and analyzes national PrEP policies across 13 South American countries through an intersectional lens, identifying challenges and opportunities for more equitable HIV prevention strategies.
methodsWe conducted a documentary survey of national PrEP-related policies, clinical guidelines, regulations, and public communications from Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Guyana, French Guiana, Paraguay, Peru, Suriname, Uruguay, and Venezuela. Searches were performed on institutional websites in Portuguese, Spanish, English, and French using predefined keywords. In the absence of official policy documents, information was collected from media and civil society sources. Data from 118 documents were coded and analyzed using iterative summative content analysis, integrating intersectionality theory to assess how policies address (or neglect) structural inequalities.
resultsTen countries have formal national PrEP policies (Argentina, Brazil, Chile, Colombia, Ecuador, Guyana, French Guiana, Paraguay, Peru, Uruguay), with Brazil pioneering implementation in 2017. Three countries (Bolivia, Suriname, Venezuela) lack comprehensive national guidelines. Most countries recommend daily oral PrEP; on-demand dosing is approved in fewer contexts, often with restrictions. Long-acting injectable cabotegravir has been approved only in Brazil, French Guiana, and Peru, but remains largely unavailable. Geographic coverage ranges from national to highly localized models. Prioritized groups include men who have sex with men, transgender women, sex workers, serodifferent couples, and, in some countries, people who use drugs. Policy formulation involves ministries of health, academia, international organizations, and, variably, civil society. However, inclusion of marginalized populations and integration of intersectional approaches remain limited. There are inequalities in the incorporation of social markers of difference in PrEP policies across the region, with greater emphasis on sexuality, gender, class, and health conditions, and limited attention to race/ethnicity, territory, generation, and disability.
conclusionPrEP policy adoption in South America demonstrates significant heterogeneity, shaped by intersecting social, political, and institutional factors. While the region has made notable advances, access remains uneven, with structural barriers such as stigma, regulatory gaps, and geographic inequities limiting impact. Incorporating intersectional perspectives into policy design and implementation is essential to ensure that PrEP - in all its modalities - is accessible as a right to health, addressing differences across multiple social, geographic, and economic dimensions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.